Skip to main content
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. logo

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. — Investor Relations & Filings

Ticker · 2315 HKEX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2026-04-27 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 2315

About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

https://www.biocytogen.com.cn

Biocytogen is a global biotechnology company focused on the discovery and development of novel antibody-based drugs and the provision of integrated preclinical research services. The company utilizes proprietary gene-editing technologies, including the SUPCE™ platform, to generate the RenMice family of fully human antibody/TCR discovery models (e.g., RenMab, RenLite, RenNano). These platforms support the development of monoclonal antibodies, bispecific antibodies, and ADCs. Biocytogen is a key provider of preclinical CRO services, offering thousands of off-the-shelf drug target humanized animal and cell models, customized gene editing, and comprehensive pharmacology studies to accelerate drug discovery from target validation to IND filing, primarily in oncology and autoimmune fields.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 1% confidence The text is a very short notice stating that an announcement has been published elsewhere, without containing any substantive report content or detailed financial information. It merely informs readers of the publication rather than presenting full report details. According to the “menu vs meal” rule, such brief notices about report releases are classified as a Report Publication Announcement (RPA).
2026-04-27 English
FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026
Interim / Quarterly Report Classification · 1% confidence The document is titled 'FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026' for Biocytogen Pharmaceuticals. It contains substantive financial data, including key accounting data, financial indicators, and a breakdown of non-recurring profit or loss items. It is not a mere announcement of a report, as it provides the actual financial tables and analysis for the specified interim period. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-04-27 English
Form of Proxy of H Shareholders for the Use at the 2025 Annual General Meeting Held on Thursday, May 21, 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a "Form of Proxy" to be used by H-shareholders at the company’s upcoming 2025 Annual General Meeting, allowing shareholders to appoint proxies and cast votes on resolutions. This is clearly part of the materials sent to shareholders to solicit their votes and provide meeting information, fitting the definition of a Proxy Solicitation & Information Statement.
2026-04-23 English
Notice of the 2025 Annual General Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Notice of the 2025 Annual General Meeting, including the meeting agenda, resolutions to be voted on, and detailed proxy and voting instructions. It is sent to shareholders to provide information for the meeting and to solicit their votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which encompasses materials sent to shareholders to request their votes and provide meeting details.
2026-04-23 English
Circular for the 2025 Annual General Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a detailed shareholder circular containing the letter from the Board, definitions, work reports, resolutions to be considered at the Annual General Meeting, and the full notice of the AGM including proxy arrangements. It is clearly a proxy solicitation information statement sent to shareholders to inform them and request their votes on various resolutions. It is not an actual annual report, earnings release, or simple announcement; it is the formal materials for soliciting proxies at the AGM. Therefore, it matches the Proxy Solicitation & Information Statement category (PSI).
2026-04-23 English
2025 Environmental, Social and Governance (ESG) Report
Regulatory Filings
2026-04-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.